Longeveron (LGVN) Stock Price, News & Analysis

Company Overview

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Key Stats

• Today's Range: $1.36 to $1.46
• 50-Day Range: $1.26 to $1.86
• 52-Week Range: $0.77 to $6.40
• Volume: 192,089 shs
• Average Volume: 2.99 million shs
• Market Capitalization: $21.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.67
• Consensus Rating: Buy

Longeveron Stock Analysis - MarketRank™

Longeveron scored higher than 62% of companies evaluated by MarketBeat, and ranked 727th out of 1,850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Longeveron has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Longeveron has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Longeveron are expected to grow in the coming year, from ($3.69) to ($1.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Longeveron is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Longeveron is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Longeveron has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.50% of the float of Longeveron has been sold short.

Short Interest Ratio / Days to Cover

Longeveron has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Longeveron has recently decreased by 16.88%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Longeveron does not currently pay a dividend.

Dividend Growth

Longeveron does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.50% of the float of Longeveron has been sold short.

Short Interest Ratio / Days to Cover

Longeveron has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Longeveron has recently decreased by 16.88%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: -0.33

News Sentiment

Longeveron has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Longeveron this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Longeveron insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,350.00 in company stock.

Percentage Held by Insiders

19.12% of the stock of Longeveron is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 10.01% of the stock of Longeveron is held by institutions.

LGVN Stock Analysis - Frequently Asked Questions

How have LGVN shares performed this year?

Longeveron's stock was trading at $1.73 at the start of the year. Since then, LGVN stock has decreased by 17.9% and is now trading at $1.42.
View the best growth stocks for 2025 here.

How were Longeveron's earnings last quarter?

Longeveron Inc. (NASDAQ:LGVN) posted its earnings results on Tuesday, November, 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.19. The business had revenue of $0.77 million for the quarter, compared to analysts' expectations of $0.34 million. Longeveron had a negative trailing twelve-month return on equity of 142.43% and a negative net margin of 967.49%.
Read the conference call transcript.

When did Longeveron's stock split?

Longeveron shares reverse split before market open on Wednesday, March 27th 2024. The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Longeveron IPO?

Longeveron (LGVN) raised $30 million in an IPO on Friday, February 12th 2021. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. acted as the underwriters for the IPO.

Who are Longeveron's major shareholders?

Top institutional investors of Longeveron include R Squared Ltd (0.16%). Insiders that own company stock include Joshua Hare, Rock Soffer, Khoso Baluch, Mohamed Wa'el Ahmed Hashad, James Clavijo, Jeffrey Pfeffer and Cathy Ross.
View institutional ownership trends.

How do I buy shares of Longeveron?

Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Longeveron own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Longeveron investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 5/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LGVN
• CIK: 1721484
• Web: www.longeveron.com
• Phone: 305-302-7158
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.67
• High Stock Price Target: $10.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +510.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-21,410,000.00
• Net Margins: -967.49%
• Pretax Margin: -967.49%
• Return on Equity: -142.43%
• Return on Assets: -100.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.67
• Quick Ratio: 7.67

Sales & Book Value

• Annual Sales: $2.23 million
• Price / Sales: 9.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.68 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 14,928,000
• Free Float: 12,000,000
• Market Cap: $21.20 million
• Optionable: Not Optionable
• Beta: 0.38